Drug intelligence / Profile preview

Lactobacillus plantarum K10

Development stage: Preclinical
Lead developer: SynbioTech Biotechnology
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Lactobacillus plantarum K10 is a specific probiotic bacterial strain being investigated as an anti-obesity live biotherapeutic candidate. Publicly available literature and patent material describe this strain as having **in vitro** inhibitory activity against digestive enzymes linked to carbohydrate and fat absorption, including alpha-amylase, alpha-glucosidase, and pancreatic lipase, and as reducing adipocyte differentiation in 3T3-L1 cells; in a high-fat-diet animal model it was reported to reduce body weight and fat mass and improve gut permeability. The available evidence appears to be preclinical rather than clinical, and the asset is best characterized as a strain-specific probiotic or microbial therapy rather than an approved pharmaceutical drug. A Korean patent describes the anti-obesity strain and gives accession number KCTC13376BP, and the published work is associated with Korea Food Research Institute and Holzapfel Effective Microbes.

Other names: L. plantarum K10

Targets

Sucrase-IsomaltaseAMY (Pancreatic alpha-amylase)GehA (Triacylglycerol lipase GehA)

Beyond the preview

Go deeper on Lactobacillus plantarum K10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lactobacillus plantarum K10.

Explore the full profile